These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 39271538)

  • 1. Bronchoalveolar lavage fluid analysis in patients with checkpoint inhibitor pneumonitis.
    Chen R; Shi Y; Fang N; Shao C; Huang H; Pan R; Xu Y; Wang M; Liu X; Xu K; Zhu R; Wang M
    Cancer Immunol Immunother; 2024 Sep; 73(11):235. PubMed ID: 39271538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The application of bronchoscopy in the assessment of immune checkpoint inhibitor-related pneumonitis severity and recurrence.
    Guo C; Zhang Q; Zhou P; Cheng Y; Nie L; Wang G
    Sci Rep; 2024 Jul; 14(1):17137. PubMed ID: 39060280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis.
    Huang A; Xu Y; Zang X; Wu C; Gao J; Sun X; Xie M; Ma X; Deng H; Song J; Ren F; Pang L; Qian J; Yu Z; Wan S; Chen Y; Pan L; Zhuang G; Liu S; Xue X
    BMC Cancer; 2021 May; 21(1):634. PubMed ID: 34051746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of cytokines in bronchoalveolar lavage fluid in patients with checkpoint inhibitor pneumonitis and pulmonary infection: A case-control study.
    Si X; Zheng X; Tian X; Wang H; Xu Y; Zhao J; Chen M; Zhong W; Wang M; Zhang L; Zhang X
    Thorac Cancer; 2023 Jul; 14(21):2038-2044. PubMed ID: 37259819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular analysis of bronchoalveolar lavage fluid to narrow differential diagnosis of checkpoint inhibitor-related pneumonitis in metastatic melanoma.
    Strippoli S; Fucci L; Negri A; Putignano D; Cisternino ML; Napoli G; Filannino R; De Risi I; Sciacovelli AM; Guida M
    J Transl Med; 2020 Dec; 18(1):473. PubMed ID: 33302981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic landscape dysregulation in bronchoalveolar lavage fluid of checkpoint inhibitor pneumonitis.
    Yu W; He Y; Shang Y; Guo T; Wang K; Liang H; Xue J; Ma X; Mu X; Li R; Gao Z
    Clin Immunol; 2023 Feb; 247():109230. PubMed ID: 36646189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Deep lung--cellular reaction to HIV].
    Tavares Marques MA; Alves V; Duque V; Botelho MF
    Rev Port Pneumol; 2007; 13(2):175-212. PubMed ID: 17492233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis.
    Suresh K; Naidoo J; Zhong Q; Xiong Y; Mammen J; de Flores MV; Cappelli L; Balaji A; Palmer T; Forde PM; Anagnostou V; Ettinger DS; Marrone KA; Kelly RJ; Hann CL; Levy B; Feliciano JL; Lin CT; Feller-Kopman D; Lerner AD; Lee H; Shafiq M; Yarmus L; Lipson EJ; Soloski M; Brahmer JR; Danoff SK; D'Alessio F
    J Clin Invest; 2019 Jul; 129(10):4305-4315. PubMed ID: 31310589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Clinical Analysis of Checkpoint Inhibitor Pneumonitis with Different Severities in Lung Cancer Patients: A Retrospective Study.
    Huang H; Chen R; Xu Y; Fang N; Shao C; Xu K; Wang M
    J Clin Med; 2024 Jan; 13(1):. PubMed ID: 38202262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential role of lung microbiota and lauroylcarnitine in T-cell activation associated with checkpoint inhibitor pneumonitis.
    Yu W; Wang K; He Y; Shang Y; Hu X; Deng X; Zhao L; Ma X; Mu X; Li R; Gao Z
    EBioMedicine; 2024 Aug; 106():105267. PubMed ID: 39098109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic immune checkpoint inhibitor pneumonitis.
    Naidoo J; Cottrell TR; Lipson EJ; Forde PM; Illei PB; Yarmus LB; Voong KR; Feller-Kopman D; Lee H; Riemer J; Wang D; Taube JM; Brahmer JR; Lin CT; Danoff SK; D'Alessio FR; Suresh K
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics and management of immune checkpoint inhibitor-related pneumonitis: A single-institution retrospective study.
    Wang H; Zhao Y; Zhang X; Si X; Song P; Xiao Y; Yang X; Song L; Shi J; Zhao H; Zhang L
    Cancer Med; 2021 Jan; 10(1):188-198. PubMed ID: 33211395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytomegalovirus infection as an underestimated trigger for checkpoint inhibitor-related pneumonitis in lung cancer: a retrospective study.
    Lin X; Lu T; Li S; Xie X; Chen X; Jiang J; Qin Y; Xie Z; Liu M; Ouyang M; Zhong N; Song Y; Zhou C
    Clin Transl Oncol; 2021 Feb; 23(2):389-396. PubMed ID: 32613413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The predict factors and clinical prognosis value of immune-related pneumonia of receiving PD-1 inhibitor in advanced non-small cell lung cancer: A retrospective study.
    Yang J; Lyu M; Feng X; Liu F; Zeng R; Sun X; Bao Z; Zhou L; Gao B; Ni L; Xiang Y
    Int Immunopharmacol; 2024 Dec; 142(Pt B):113140. PubMed ID: 39312858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A case of Sairei-to-induced pneumonitis diagnosed by lymphocyte stimulation test of bronchoalveolar lavage fluid].
    Maeno T; Ubukata M; Maeno Y; Suga T; Motegi M; Takayanagi N; Takahashi M; Nagai R
    Nihon Kyobu Shikkan Gakkai Zasshi; 1997 Dec; 35(12):1347-51. PubMed ID: 9567079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical features and prognostic analysis of checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer].
    Chen RX; Liu XN; Xu Y; Shi YJ; Wang MQ; Shao C; Huang H; Xu K; Wang MZ; Xu ZJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2024 Mar; 47(3):207-213. PubMed ID: 38448169
    [No Abstract]   [Full Text] [Related]  

  • 17. Spectrum of CD4 to CD8 T-cell ratios in lymphocytic alveolitis associated with methotrexate-induced pneumonitis.
    Fuhrman C; Parrot A; Wislez M; Prigent H; Boussaud V; Bernaudin JF; Mayaud C; Cadranel J
    Am J Respir Crit Care Med; 2001 Oct; 164(7):1186-91. PubMed ID: 11673207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitor-related interstitial lung disease.
    Suzuki K; Yanagihara T; Matsumoto K; Kusaba H; Yamauchi T; Ikematsu Y; Tanaka K; Otsubo K; Inoue H; Yoneshima Y; Iwama E; Arimura-Omori M; Harada E; Hamada N; Okamoto I; Nakanishi Y
    Int Immunol; 2020 Jul; 32(8):547-557. PubMed ID: 32253426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Manifestation, Risk Factors, and Immune Checkpoint Inhibitor Rechallenge of Checkpoint Inhibitor-Associated Pneumonitis in Patients With Lung Cancer.
    Li X; Yang F; Liu B; Ye L; Du J; Fan X; Yu Y; Li M; Bu L; Zhang Z; Xie L; Li W; Qi J
    J Immunother; 2024 Jul-Aug 01; 47(6):220-226. PubMed ID: 38618919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications.
    Kim ST; Sheshadri A; Shannon V; Kontoyiannis DP; Kantarjian H; Garcia-Manero G; Ravandi F; Im JS; Boddu P; Bashoura L; Balachandran DD; Evans SE; Faiz S; Ruiz Vazquez W; Divenko M; Mathur R; Tippen SP; Gumbs C; Neelapu SS; Naing A; Wang L; Diab A; Futreal A; Nurieva R; Daver N
    Front Immunol; 2020; 11():590494. PubMed ID: 33552049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.